Company Overview and News

Oro Verde samples high grade gold in Nicaragua

Oro Verde Ltd (ASX:OVL) has received high grade gold results from trenching at the Topacio project in Nicaragua.
Upvote Downvote

Couran Cove Rewards Launches on Queensland's Gold Coast

2017-04-04 prnewswire
NEWPORT BEACH, Calif., April 3, 2017 /PRNewswire/ -- Iconic Australian getaway Couran Cove Island Resort has partnered with global loyalty rewards network VOILÀ Hotel Rewards ( to launch the Couran Cove Rewards Program and entice even more local and international visitors to experience its truly unique natural charm.
Upvote Downvote

Oro Verde: Access latest PPT from Proactive's CEO Sessions

Oro Verde's (ASX:OVL) managing director, Trevor Woolfe, joined Proactive's CEO Sessions in Sydney on Monday 20th February and Melbourne on Tuesday 21st February.
Upvote Downvote

Oro Verde to talk gold hunt with Newcrest at Proactive's Spotlight CEO Sessions

Oro Verde (ASX:OVL) has received all the permits to get the diamond rig spinning at the Topacio Gold Project in Nicaragua.
Upvote Downvote

Oro Verde to begin gold drilling in Nicaragua with Newcrest Mining

Oro Verde (ASX:OVL) is commencing a diamond drill program funded by Newcrest Mining (ASX:NCM) at the Topacio Gold Project, located in southeastern Nicaragua.
Upvote Downvote

Verdant Minerals to update on next phosphate steps at Proactive's CEO Spotlight Sessions

Product characterisation and specification pilot scale test work has commenced with a 40 tonne bulk sample mined and dispatched from site.
Upvote Downvote

Danakali brings world-class potash to Proactive's Spotlight CEO Sessions

Danakali (ASX:DNK) is focused on the world-class, tier 1 asset, the Colluli Potash Project in Eritrea.
Upvote Downvote

PNX Metals swells resources in time for Proactive's Spotlight CEO Sessions

PNX Metals (ASX:PNX) has continued to intersect mineralisation at the Hayes Creek project in the Northern Territory during 2016.
Upvote Downvote

Oro Verde Ltd and Newcrest moving on to the next phase at Topacio Gold

Newcrest International is a wholly owned subsidiary of Newcrest Mining Ltd (ASX:NCM). The drilling will follow first year Stage 1 exploration program of the farm-in agreement between Newcrest and Oro Verde, which has been completed successfully. Highly encouraging mapping, sampling, soil geochemistry and airborne geophysics results from the program has highlighted a number of target areas that require drill testing.
Upvote Downvote

Oro Verde Ltd secures cash to advance gold project with Newcrest

Oro Verde Ltd (ASX:OVL) has agreed to place 70 million shares to institutional and sophisticated investors priced at $0.012 to raise $840,000. Funds raised will be used to advance the company’s gold projects in Nicaragua as well as for general working capital. Oro Verde and joint venture partner, Newcrest Mining Ltd (ASX:NCM) aim to discover multi-million ounce, high grade, epithermal gold deposits at the Topacio Gold Project located in Nicaragua.
Upvote Downvote

Oro Verde Ltd in an ASX trading halt

Oro Verde Ltd (ASX:OVL) has been granted a trading halt by the ASX this morning, pending details of a capital raising. The halt will remain in place until the opening of trade on Friday 26th August 2016, or earlier if an announcement is made to the market.
Upvote Downvote

VOILÀ Hotel Rewards Celebrates Launch of Parkway Plaza Rewards in Casper, Wyoming

2016-05-17 prnewswire
NEWPORT BEACH, Calif., May 17, 2016 /PRNewswire/ -- VOILÀ Hotel Rewards ( is proud to announce the launch of Parkway Plaza Rewards (, a new co-branded reward program created for the Parkway Plaza Hotel and Convention Center. The launch of Parkway Plaza Rewards reflects VOILÀ's commitment to increasing its network across the United States.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN:, Inc Analysis and Research Report

11h - Asif

Overview opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...